Concepedia

Karen Hande

KH

Statistics

Publications

6

Citations

441

H-Index

6

Active since

1983

Affiliations

Dana-Farber Cancer Institute(Current)

Millennium Engineering and Integration (United States)

Massachusetts General Hospital

Roswell Park Comprehensive Cancer Center

Emory University

Karen Hande is an author at Dana-Farber Cancer Institute specializing in oncology, radiation oncology, and medicine.

Top concepts

Publications per year

1983–2008

6

Publications

6

Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw

Noopur Raje, Sook-Bin Woo, Karen Hande et al. · Clinical Cancer Research · 2008 · 147 citations

High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study.

S N Wolff, Mehmet F. Fer, Catharine McKay et al. · Journal of Clinical Oncology · 1983 · 107 citations

, , +17

Cisplatin and etoposide combination chemotherapy for refractory small cell carcinoma of the lung

L. L. Porter, David H. Johnson, John D. Hainsworth et al. · Lung Cancer · 1986 · 72 citations

, , +6

Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM).

Paul G. Richardson, Asher Chanan‐Khan, Robert Schlossman et al. · Blood · 2004 · 57 citations

A Phase 1 Trial of Lenalidomide (REVLIMID®) with Bortezomib (VELCADE®) in Relapsed and Refractory Multiple Myeloma.

Paul G. Richardson, R Schlossman, Nikhil C. Munshi et al. · Blood · 2005 · 35 citations

1–5 of 6